Literature DB >> 26858198

Induction chemotherapy-based larynx preservation program for locally advanced hypopharyngeal cancer: oncologic and functional outcomes and prognostic factors.

Alexandre Bozec1, Karen Benezery2, Marc Ettaiche3, Emmanuel Chamorey3, Clair Vandersteen4, Olivier Dassonville4, Gilles Poissonnet4, Jean-Christophe Riss4, Jean-Michel Hannoun-Lévi2, Marie-Eve Chand2, Axel Leysalle2, Esma Saada5, Joël Guigay5, Anne Sudaka6, François Demard4, José Santini4, Frédéric Peyrade5.   

Abstract

To evaluate oncologic and functional outcomes and prognostic factors in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy (ICT)-based larynx preservation program in daily clinical practice. All patients with locally advanced (T3/4, N0-3, M0) hypopharyngeal squamous cell carcinoma, technically suitable for total pharyngo-laryngectomy, treated by docetaxel (75 mg/m(2), day 1), cisplatin (75 mg/m(2), day 1) and 5-fluorouracil (750 mg/m(2)/day, day 1-5) (TPF)-ICT (2-3 cycles) for larynx preservation at our institution between 2004 and 2013, were included in this retrospective study. Prognostic factors of oncologic (overall, cause-specific and recurrence-free survival: OS, SS and RFS) and functional (dysphagia outcome and severity scale, permanent enteral nutrition, larynx preservation) outcomes were assessed in univariate and multivariate analyses. A total of 53 patients (42 men and 11 women, mean age 58.6 ± 8.2 years) were included in this study. Grade 3-4 toxicities were experienced by 17 (32 %) patients during ICT. The rate of poor response (response <50 % without larynx remobilization) to ICT was 10 %. At 5 years, OS, SS and RFS rates were 56, 60 and 54 %, respectively. Four patients required definitive enteral nutrition (permanent enteral tube feeding). The rate of patients alive, disease-free and with a functional larynx at 2 years was 58 %. T4 tumor stage (p = 0.005) and response to ICT <50 % (p = 0.02) were independent prognostic factors of OS. Response to ICT was significantly associated with the risk of permanent enteral nutrition (p = 0.04) and larynx preservation (p = 0.01). In daily clinical practice, a TPF-ICT-based larynx preservation protocol can be used in patients with locally advanced hypopharyngeal cancer with satisfactory results in terms of tolerance, efficacy and oncologic and functional outcomes.

Entities:  

Keywords:  Cancer; Functional outcome; Hypopharynx; Induction chemotherapy; Larynx preservation; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 26858198     DOI: 10.1007/s00405-016-3919-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  14 in total

1.  Ten years single institutional experience of treatment for advanced hypopharyngeal cancer in Kyoto University.

Authors:  Shigeru Hirano; Ichiro Tateya; Morimasa Kitamura; Shinpei Kada; Seiji Ishikawa; Tomoko Kanda; Shinzo Tanaka; Juichi Ito
Journal:  Acta Otolaryngol Suppl       Date:  2010-11

2.  The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy.

Authors:  Beste M Atasoy; Oya Yonal; Birsen Demirel; Faysal Dane; Yusuf Yilmaz; Cem Kalayci; Ufuk Abacioglu; Nese Imeryuz
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-04-07       Impact factor: 2.503

3.  The Dysphagia Outcome and Severity Scale.

Authors:  K H O'Neil; M Purdy; J Falk; L Gallo
Journal:  Dysphagia       Date:  1999       Impact factor: 3.438

4.  Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.

Authors:  M R Posner; C M Norris; L J Wirth; D M Shin; K J Cullen; E W Winquist; C R Blajman; E A Mickiewicz; G P Frenette; L F Plinar; R B Cohen; L M Steinbrenner; J M Freue; V A Gorbunova; S A Tjulandin; L E Raez; D R Adkins; R B Tishler; M R Roessner; R I Haddad
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

5.  Gastrostomy tube placement in patients with hypopharyngeal cancer treated with radiotherapy or chemoradiotherapy: factors affecting placement and dependence.

Authors:  Mihir K Bhayani; Katherine A Hutcheson; Denise A Barringer; Dianna B Roberts; Jan S Lewin; Stephen Y Lai
Journal:  Head Neck       Date:  2013-01-16       Impact factor: 3.147

6.  [Total pharyngolaryngectomy in the 21st century: indications, oncologic and functional outcomes].

Authors:  B Agopian; O Dassonville; E Chamorey; G Poissonnet; C S Pierre; F Peyrade; C Hebert; K Benezery; D Viel; A Sudaka; J Vallicioni; F Demard; J Santini; A Bozec
Journal:  Rev Laryngol Otol Rhinol (Bord)       Date:  2011

7.  Intensity modulated radiotherapy with concurrent chemotherapy for larynx preservation of advanced resectable hypopharyngeal cancer.

Authors:  Wen-Yen Huang; Yee-Min Jen; Chang-Ming Chen; Yu-Fu Su; Chun-Shu Lin; Yaoh-Shiang Lin; Ying-Nan Chang; Hsing-Lung Chao; Kuen-Tze Lin; Li-Ping Chang
Journal:  Radiat Oncol       Date:  2010-05-15       Impact factor: 3.481

8.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

9.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.

Authors:  Yoann Pointreau; Pascal Garaud; Sophie Chapet; Christian Sire; Claude Tuchais; Jacques Tortochaux; Sandrine Faivre; Stephane Guerrif; Marc Alfonsi; Gilles Calais
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

10.  Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary.

Authors:  Jean-Louis Lefebvre; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-01       Impact factor: 7.038

View more
  2 in total

1.  Nimotuzumab Combined with Induction Chemotherapy and Concurrent Chemoradiotherapy in Unresectable Locally Advanced Hypopharyngeal Carcinoma: A Single Institution Experience in China.

Authors:  Xin Tian; Ying Xuan; Rong Wu; Song Gao
Journal:  Cancer Manag Res       Date:  2020-05-11       Impact factor: 3.989

2.  Nursing Observation on the Clinical Efficacy and Toxicity of Lobaplatin Compared with Cisplatin in the Treatment of Locally Advanced Hypopharyngeal Carcinoma Based on Intelligent CT Imaging.

Authors:  Yunyan Li; Guangrun Yang; Mengmeng Li; Xu Tong
Journal:  J Healthc Eng       Date:  2021-06-30       Impact factor: 2.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.